6834 related articles for article (PubMed ID: 24403862)
21. Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model.
Yan J; Tingey C; Lyde R; Gorham TC; Choo DK; Muthumani A; Myles D; Weiner LP; Kraynyak KA; Reuschel EL; Finkel TH; Kim JJ; Sardesai NY; Ugen KE; Muthumani K; Weiner DB
Cancer Gene Ther; 2014 Dec; 21(12):507-17. PubMed ID: 25394503
[TBL] [Abstract][Full Text] [Related]
22. A
Alter C; Ding Z; Flögel U; Scheller J; Schrader J
Am J Physiol Heart Circ Physiol; 2019 Jul; 317(1):H190-H200. PubMed ID: 31050560
[TBL] [Abstract][Full Text] [Related]
23. α-Galactosylceramide but not phenyl-glycolipids induced NKT cell anergy and IL-33-mediated myeloid-derived suppressor cell accumulation via upregulation of egr2/3.
Huang JR; Tsai YC; Chang YJ; Wu JC; Hung JT; Lin KH; Wong CH; Yu AL
J Immunol; 2014 Feb; 192(4):1972-81. PubMed ID: 24465013
[TBL] [Abstract][Full Text] [Related]
24. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors.
Beavis PA; Divisekera U; Paget C; Chow MT; John LB; Devaud C; Dwyer K; Stagg J; Smyth MJ; Darcy PK
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14711-6. PubMed ID: 23964122
[TBL] [Abstract][Full Text] [Related]
25. Recruitment of a myeloid cell subset (CD11b/Gr1 mid) via CCL2/CCR2 promotes the development of colorectal cancer liver metastasis.
Zhao L; Lim SY; Gordon-Weeks AN; Tapmeier TT; Im JH; Cao Y; Beech J; Allen D; Smart S; Muschel RJ
Hepatology; 2013 Feb; 57(2):829-39. PubMed ID: 23081697
[TBL] [Abstract][Full Text] [Related]
26. Targeting Ornithine Decarboxylase by α-Difluoromethylornithine Inhibits Tumor Growth by Impairing Myeloid-Derived Suppressor Cells.
Ye C; Geng Z; Dominguez D; Chen S; Fan J; Qin L; Long A; Zhang Y; Kuzel TM; Zhang B
J Immunol; 2016 Jan; 196(2):915-23. PubMed ID: 26663722
[TBL] [Abstract][Full Text] [Related]
27. AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells.
Maenhout SK; Du Four S; Corthals J; Neyns B; Thielemans K; Aerts JL
Oncotarget; 2014 Aug; 5(16):6801-15. PubMed ID: 25149535
[TBL] [Abstract][Full Text] [Related]
28. NK1.1 cells and CD8 T cells mediate the antitumor activity of Cl-IB-MECA in a mouse melanoma model.
Morello S; Sorrentino R; Montinaro A; Luciano A; Maiolino P; Ngkelo A; Arra C; Adcock IM; Pinto A
Neoplasia; 2011 Apr; 13(4):365-73. PubMed ID: 21472141
[TBL] [Abstract][Full Text] [Related]
29. Adenosine A2B receptor blockade slows growth of bladder and breast tumors.
Cekic C; Sag D; Li Y; Theodorescu D; Strieter RM; Linden J
J Immunol; 2012 Jan; 188(1):198-205. PubMed ID: 22116822
[TBL] [Abstract][Full Text] [Related]
30. Ovarian cancer modulates the immunosuppressive function of CD11b
Udumula MP; Sakr S; Dar S; Alvero AB; Ali-Fehmi R; Abdulfatah E; Li J; Jiang J; Tang A; Buekers T; Morris R; Munkarah A; Giri S; Rattan R
Mol Metab; 2021 Nov; 53():101272. PubMed ID: 34144215
[TBL] [Abstract][Full Text] [Related]
31. Lack of Muc1-regulated beta-catenin stability results in aberrant expansion of CD11b+Gr1+ myeloid-derived suppressor cells from the bone marrow.
Poh TW; Bradley JM; Mukherjee P; Gendler SJ
Cancer Res; 2009 Apr; 69(8):3554-62. PubMed ID: 19351842
[TBL] [Abstract][Full Text] [Related]
32. CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma.
Umansky V; Blattner C; Gebhardt C; Utikal J
Cancer Immunol Immunother; 2017 Aug; 66(8):1015-1023. PubMed ID: 28382399
[TBL] [Abstract][Full Text] [Related]
33. Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell-Mediated Tumor Immunity.
Büll C; Boltje TJ; Balneger N; Weischer SM; Wassink M; van Gemst JJ; Bloemendal VR; Boon L; van der Vlag J; Heise T; den Brok MH; Adema GJ
Cancer Res; 2018 Jul; 78(13):3574-3588. PubMed ID: 29703719
[TBL] [Abstract][Full Text] [Related]
34. Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion.
Tengesdal IW; Menon DR; Osborne DG; Neff CP; Powers NE; Gamboni F; Mauro AG; D'Alessandro A; Stefanoni D; Henen MA; Mills TS; De Graaf DM; Azam T; Vogeli B; Palmer BE; Pietras EM; DeGregori J; Tan AC; Joosten LAB; Fujita M; Dinarello CA; Marchetti C
Proc Natl Acad Sci U S A; 2021 Mar; 118(10):. PubMed ID: 33649199
[TBL] [Abstract][Full Text] [Related]
35. Icaritin promotes tumor T-cell infiltration and induces antitumor immunity in mice.
Hao H; Zhang Q; Zhu H; Wen Y; Qiu D; Xiong J; Fu X; Wu Y; Meng K; Li J
Eur J Immunol; 2019 Dec; 49(12):2235-2244. PubMed ID: 31465113
[TBL] [Abstract][Full Text] [Related]
36. Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis.
Wang Z; Liu JQ; Liu Z; Shen R; Zhang G; Xu J; Basu S; Feng Y; Bai XF
J Immunol; 2013 Mar; 190(5):2415-23. PubMed ID: 23345334
[TBL] [Abstract][Full Text] [Related]
37. Targeting the adenosine A2b receptor in the tumor microenvironment overcomes local immunosuppression by myeloid-derived suppressor cells.
Morello S; Miele L
Oncoimmunology; 2014; 3():e27989. PubMed ID: 25101221
[TBL] [Abstract][Full Text] [Related]
38. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8
Yin W; Song Y; Liu Q; Wu Y; He R
Immunology; 2017 Oct; 152(2):287-297. PubMed ID: 28556970
[TBL] [Abstract][Full Text] [Related]
39. Chemerin partly mediates tumor-inhibitory effect of all-trans retinoic acid via CMKLR1-dependent natural killer cell recruitment.
Song Y; Yin W; Dan Y; Sheng J; Zeng Y; He R
Immunology; 2019 Jul; 157(3):248-256. PubMed ID: 31063220
[TBL] [Abstract][Full Text] [Related]
40. Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment.
van Hooren L; Georganaki M; Huang H; Mangsbo SM; Dimberg A
Oncotarget; 2016 Jul; 7(31):50277-50289. PubMed ID: 27385210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
